Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia

Matthew J. Maurer; James R. Cerhan; Jerry A. Katzmann; Brian K. Link; Cristine Allmer; Clive S. Zent; Timothy G. Call; Kari G. Rabe; Curtis A. Hanson; Neil E. Kay; Susan L. Slager; Thomas E. Witzig; Tait D. Shanafelt

doi:10.1182/blood-2011-04-349134

Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia

Matthew J. Maurer, James R. Cerhan, Jerry A. Katzmann, Brian K. Link, Cristine Allmer, Clive S. Zent, Timothy G. Call, Kari G. Rabe, Curtis A. Hanson, Neil E. Kay, Susan L. Slager, Thomas E. Witzig, Tait D. Shanafelt

Research output: Contribution to journal › Article › peer-review

39 Scopus citations

Abstract

Free light chains (FLCs) are the most commonly detected paraproteins in chronic lymphocytic leukemia (CLL). We examined the types of FLC abnormalities and prognostic utility of the FLC assay compared with standard prognostic biomarkers in a prospective cohort of 339 patients with newly diagnosed CLL. Three types of FLC abnormalities were identified: monoclonal elevated FLC (elevated κ and/or λ with abnormal FLC ratio), polyclonal elevated FLC (elevated κ and/or λ with normal FLC ratio), and ratio-only FLC abnormality (normal range κ and λ with abnormal FLC ratio). One hundred sixty-five patients (49%) had a FLC abnormality with approximately equal distribution among monoclonal elevation, polyclonal elevation, and ratio-only abnormality. All FLC abnormalities were associated with poor time to first treatment: monoclonal FLC (hazard ratio [HR], 4.99; 95% confidence interval [CI], 2.94-8.48), polyclonal FLC (HR, 2.40; 95% CI, 1.24-4.64), ratio-only FLC (HR, 2.57; 95% CI, 1.40-4.69). Monoclonal FLC and polyclonal FLC were associated with poor overall survival compared with patients with normal FLC. Results remained significant after adjusting for Rai stage. The FLC assay is a simple, widely available clinical test with similar prognostic utility as routinely used prognostic biomarkers for CLL. Among persons with FLC abnormalities, the type of abnormality affects prognostic significance.

Original language	English (US)
Pages (from-to)	2821-2826
Number of pages	6
Journal	Blood
Volume	118
Issue number	10
DOIs	https://doi.org/10.1182/blood-2011-04-349134
State	Published - Sep 8 2011

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/blood-2011-04-349134

Cite this

Maurer, M. J., Cerhan, J. R., Katzmann, J. A., Link, B. K., Allmer, C., Zent, C. S., Call, T. G., Rabe, K. G., Hanson, C. A., Kay, N. E., Slager, S. L., Witzig, T. E., & Shanafelt, T. D. (2011). Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia. Blood, 118(10), 2821-2826. https://doi.org/10.1182/blood-2011-04-349134

@article{2f2587e829b14661bcb9790086ed9a4f,

title = "Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia",

abstract = "Free light chains (FLCs) are the most commonly detected paraproteins in chronic lymphocytic leukemia (CLL). We examined the types of FLC abnormalities and prognostic utility of the FLC assay compared with standard prognostic biomarkers in a prospective cohort of 339 patients with newly diagnosed CLL. Three types of FLC abnormalities were identified: monoclonal elevated FLC (elevated κ and/or λ with abnormal FLC ratio), polyclonal elevated FLC (elevated κ and/or λ with normal FLC ratio), and ratio-only FLC abnormality (normal range κ and λ with abnormal FLC ratio). One hundred sixty-five patients (49%) had a FLC abnormality with approximately equal distribution among monoclonal elevation, polyclonal elevation, and ratio-only abnormality. All FLC abnormalities were associated with poor time to first treatment: monoclonal FLC (hazard ratio [HR], 4.99; 95% confidence interval [CI], 2.94-8.48), polyclonal FLC (HR, 2.40; 95% CI, 1.24-4.64), ratio-only FLC (HR, 2.57; 95% CI, 1.40-4.69). Monoclonal FLC and polyclonal FLC were associated with poor overall survival compared with patients with normal FLC. Results remained significant after adjusting for Rai stage. The FLC assay is a simple, widely available clinical test with similar prognostic utility as routinely used prognostic biomarkers for CLL. Among persons with FLC abnormalities, the type of abnormality affects prognostic significance.",

author = "Maurer, {Matthew J.} and Cerhan, {James R.} and Katzmann, {Jerry A.} and Link, {Brian K.} and Cristine Allmer and Zent, {Clive S.} and Call, {Timothy G.} and Rabe, {Kari G.} and Hanson, {Curtis A.} and Kay, {Neil E.} and Slager, {Susan L.} and Witzig, {Thomas E.} and Shanafelt, {Tait D.}",

year = "2011",

month = sep,

day = "8",

doi = "10.1182/blood-2011-04-349134",

language = "English (US)",

volume = "118",

pages = "2821--2826",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "10",

}

TY - JOUR

T1 - Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia

AU - Maurer, Matthew J.

AU - Cerhan, James R.

AU - Katzmann, Jerry A.

AU - Link, Brian K.

AU - Allmer, Cristine

AU - Zent, Clive S.

AU - Call, Timothy G.

AU - Rabe, Kari G.

AU - Hanson, Curtis A.

AU - Kay, Neil E.

AU - Slager, Susan L.

AU - Witzig, Thomas E.

AU - Shanafelt, Tait D.

PY - 2011/9/8

Y1 - 2011/9/8

N2 - Free light chains (FLCs) are the most commonly detected paraproteins in chronic lymphocytic leukemia (CLL). We examined the types of FLC abnormalities and prognostic utility of the FLC assay compared with standard prognostic biomarkers in a prospective cohort of 339 patients with newly diagnosed CLL. Three types of FLC abnormalities were identified: monoclonal elevated FLC (elevated κ and/or λ with abnormal FLC ratio), polyclonal elevated FLC (elevated κ and/or λ with normal FLC ratio), and ratio-only FLC abnormality (normal range κ and λ with abnormal FLC ratio). One hundred sixty-five patients (49%) had a FLC abnormality with approximately equal distribution among monoclonal elevation, polyclonal elevation, and ratio-only abnormality. All FLC abnormalities were associated with poor time to first treatment: monoclonal FLC (hazard ratio [HR], 4.99; 95% confidence interval [CI], 2.94-8.48), polyclonal FLC (HR, 2.40; 95% CI, 1.24-4.64), ratio-only FLC (HR, 2.57; 95% CI, 1.40-4.69). Monoclonal FLC and polyclonal FLC were associated with poor overall survival compared with patients with normal FLC. Results remained significant after adjusting for Rai stage. The FLC assay is a simple, widely available clinical test with similar prognostic utility as routinely used prognostic biomarkers for CLL. Among persons with FLC abnormalities, the type of abnormality affects prognostic significance.

AB - Free light chains (FLCs) are the most commonly detected paraproteins in chronic lymphocytic leukemia (CLL). We examined the types of FLC abnormalities and prognostic utility of the FLC assay compared with standard prognostic biomarkers in a prospective cohort of 339 patients with newly diagnosed CLL. Three types of FLC abnormalities were identified: monoclonal elevated FLC (elevated κ and/or λ with abnormal FLC ratio), polyclonal elevated FLC (elevated κ and/or λ with normal FLC ratio), and ratio-only FLC abnormality (normal range κ and λ with abnormal FLC ratio). One hundred sixty-five patients (49%) had a FLC abnormality with approximately equal distribution among monoclonal elevation, polyclonal elevation, and ratio-only abnormality. All FLC abnormalities were associated with poor time to first treatment: monoclonal FLC (hazard ratio [HR], 4.99; 95% confidence interval [CI], 2.94-8.48), polyclonal FLC (HR, 2.40; 95% CI, 1.24-4.64), ratio-only FLC (HR, 2.57; 95% CI, 1.40-4.69). Monoclonal FLC and polyclonal FLC were associated with poor overall survival compared with patients with normal FLC. Results remained significant after adjusting for Rai stage. The FLC assay is a simple, widely available clinical test with similar prognostic utility as routinely used prognostic biomarkers for CLL. Among persons with FLC abnormalities, the type of abnormality affects prognostic significance.

UR - http://www.scopus.com/inward/record.url?scp=80052648801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052648801&partnerID=8YFLogxK

U2 - 10.1182/blood-2011-04-349134

DO - 10.1182/blood-2011-04-349134

M3 - Article

C2 - 21765023

AN - SCOPUS:80052648801

SN - 0006-4971

VL - 118

SP - 2821

EP - 2826

JO - Blood

JF - Blood

IS - 10

ER -

Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this